G1 Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

G1 Therapeutics

26/02/2024 14:17

* G1 Therapeutics Inc  GTHX.OQ   GTHX.O  is expected to show
a
rise in quarterly revenue when it reports  results on February
28 for the period ending December 31 2023
    * The Research Triangle Park North Carolina-based  company
is
expected to report a 27.6% increase in revenue to $13.079
million from $10.25 million a year ago, according to the mean
estimate from 6 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for G1 Therapeutics Inc is
for a
loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for G1
Therapeutics
Inc is $8.50​, above​ its last closing price of $2.22. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.32       -0.33      -0.35     Missed  -6.4
 Jun. 30 2023  -0.11       -0.22      0.14      Beat    164
 Mar. 31 2023  -0.62       -0.64      -0.53     Beat    17.2​
 Dec. 31 2022  -0.84       -0.84      -0.73     Beat    13.5
 ​​Sep.        -0.61       -0.63      -0.59     Beat    6.7
 30 2022                                                
 Jun. 30 2022  -1.02       -1.02      -0.92     Beat    9.7​
 Mar. 31 2022  -0.97       -0.97      -1.15     Missed  -18
 Dec. 31 2021  -1.03       -1.03      -0.94     Beat    9.2
 This summary was machine generated February 26 at 14:17 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)